摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-甲基-3-己醇 | 623-55-2

中文名称
5-甲基-3-己醇
中文别名
2-甲基-4-己醇;乙基异丁基甲醇
英文名称
(+-)-5-methyl-3-hexanol
英文别名
5-Methyl-3-hexanol;5-methylhexan-3-ol
5-甲基-3-己醇化学式
CAS
623-55-2
化学式
C7H16O
mdl
——
分子量
116.203
InChiKey
RGCZULIFYUPTAR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    -30.45°C (estimate)
  • 沸点:
    147°C
  • 密度:
    0.8290
  • LogP:
    2.055 (est)
  • 保留指数:
    838;838;838
  • 稳定性/保质期:
    - 存在于主流烟气中。

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    8
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    20.2
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2905199090
  • 储存条件:
    室温

SDS

SDS:5a58f847c5a2a3a2e81173ee266ce02d
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    —— (S)-5-methylhexan-3-ol 93031-24-4 C7H16O 116.203

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    铁催化剂上醇和酮的有效气相脱氧
    摘要:
    讨论了一种在600 K和1-2·10 5 Pa下铁催化剂上将醇和酮气相脱氧为烃的方法。
    DOI:
    10.1016/s0040-4039(00)98301-1
  • 作为产物:
    描述:
    乙基异丁酮三(五氟苯基)硼烷氢气 作用下, 以 乙醚 为溶剂, 70.0 ℃ 、6.08 MPa 条件下, 反应 12.0h, 生成 5-甲基-3-己醇
    参考文献:
    名称:
    Enabling Catalytic Ketone Hydrogenation by Frustrated Lewis Pairs
    摘要:
    Hydrogenation of alkyl and aryl ketones using H-2 is catalytically achieved in 18 examples using 5 mol % B(C6F5)(3) in an ethereal solvent. In these cases the borane and ether behave as a frustrated Lewis pair to activate H-2 and effect the reduction.
    DOI:
    10.1021/ja508829x
点击查看最新优质反应信息

文献信息

  • Revision of species of the “<i>Oligia</i>” <i>semicana</i> group (Lepidoptera: Noctuidae) with descriptions of a new genus and 12 new species
    作者:James T. Troubridge、J. Donald Lafontaine
    DOI:10.4039/ent134157-2
    日期:2002.4
    Abstract

    The name Neoligiagen.nov. is proposed for the “Oligiasemicana (Walker) species group in North America and 12 species, N. rubirena sp.nov., N. pagosa sp.nov., N. hardwicki sp.nov., N. inermis sp.nov., N. invenusta sp.nov., N. albirena sp.nov., N. lancea sp.nov., N. elephas sp.nov., N. lillooet sp.nov., N. surdirena sp.nov., N. canadensis sp.nov., and N. atlantica sp.nov. are described. Hadenella laevigata Smith is synonymized (synonymy restored) under Hadena tonsa Grote and Hadena hausta Grote is synonymized (synonymy restored) under Miana semicana Walker. Adults of all species are illustrated as well as male and female genitalia, where known.

    AbstractThe name Neoligiagen.nov. is proposed for the "Oligia" semicana (Walker) species group in North America and 12 species, N. rubirena sp.nov., N. pagosa sp.nov., N. hardwicki sp.nov、N. inermis sp.nov.、N. invenusta sp.nov.、N. albirena sp.nov.、N. lancea sp.nov.、N. elephas sp.nov.、N. lillooet sp.nov.、N. surdirena sp.nov.、N. canadensis sp.nov.和 N. atlantica sp.nov.等 12 个种。Hadenella laevigata Smith 与 Hadena tonsa Grote 同源(同义恢复),Hadena hausta Grote 与 Miana semicana Walker 同源(同义恢复)。所有物种的成体以及已知的雄性和雌性生殖器均附有插图。
  • NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
    申请人:Seiwert Scott D.
    公开号:US20090269305A1
    公开(公告)日:2009-10-29
    The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
    该实施例提供了一般式I、II、III、IV、V、VI、VII和X的化合物,以及包括药物组合物在内的组合物,其中包括一种主体化合物。该实施例还提供了治疗方法,包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法,这些方法通常涉及向需要的个体施用一种主体化合物或组合物的有效量。
  • COMPOUNDS USEFUL AS IMMUNOMODULATORS
    申请人:BRISTOL-MYERS SQUIBB COMPANY
    公开号:US20170107202A1
    公开(公告)日:2017-04-20
    The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    本发明公开一般涉及可用作免疫调节剂的化合物。本发明提供了化合物、包含此类化合物的组合物及其使用方法。本发明还涉及包含至少一种根据本发明的化合物的药物组合物,这些药物组合物可用于治疗各种疾病,包括癌症和传染病。
  • New Strategies in Carbonylation Chemistry:  The Synthesis of δ-Lactones from Saturated Alcohols and CO
    作者:Shinji Tsunoi、Ilhyong Ryu、Tohru Okuda、Minoru Tanaka、Mitsuo Komatsu、Noboru Sonoda
    DOI:10.1021/ja9807892
    日期:1998.9.1
    δ-carbonylation of saturated alcohols which uses a 1,5-hydrogen-transfer reaction of alkoxyl radicals and subsequent carbonylation at the δ-carbon atoms as the key. The carbonylation reactions of five classes of saturated alcohols, namely, primary alcohols having primary δ-carbons, primary alcohols having secondary δ-carbons, primary alcohols having tertiary δ-carbons, secondary alcohols having primary δ-carbons
    本文描述了饱和醇的 δ-羰基化反应,它以烷氧基的 1,5-氢转移反应和随后在 δ-碳原子上的羰基化反应为关键。5类饱和醇的羰基化反应,即具有伯δ-碳的伯醇、具有仲δ-碳的伯醇、具有叔δ-碳的伯醇、具有伯δ-碳的仲醇、具有仲δ-碳的仲醇进行了碳,其中四乙酸铅(LTA)用作单电子氧化剂以产生烷氧基自由基。除了具有叔 δ-碳的伯醇外,这些饱和醇的羰基化以中等至良好的产率得到 δ-内酯。
  • Novel high affinity thiophene-based and furan-based kinase ligands
    申请人:Deng Yongqi
    公开号:US20070043045A1
    公开(公告)日:2007-02-22
    Inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.
    描述了抑制细胞周期依赖性激酶2(CDK-2)的抑制剂、包括这些抑制剂的组合物,以及使用这些抑制剂和抑制剂组合物的方法。这些抑制剂和包括它们的组合物对于治疗疾病或疾病症状是有用的。该发明还提供了制备CDK-2抑制剂化合物的方法、抑制CDK-2的方法,以及治疗疾病或疾病症状的方法。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
mass
查看更多图谱数据,请前往“摩熵化学”平台
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台